On Monday, Gain Therapeutics Inc (NASDAQ: GANX) opened lower -6.60% from the last session, before settling in for the closing price of $1.97. Price fluctuations for GANX have ranged from $0.95 to $3.19 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -37.02%. Company’s average yearly earnings per share was noted 26.97% at the time writing. With a float of $34.19 million, this company’s outstanding shares have now reached $35.95 million.
Let’s determine the extent of company efficiency that accounts for 25 employees.
Gain Therapeutics Inc (GANX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Gain Therapeutics Inc is 4.90%, while institutional ownership is 10.54%.
Gain Therapeutics Inc (GANX) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.17 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.21) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 26.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.67% during the next five years compared to -37.02% drop over the previous five years of trading.
Gain Therapeutics Inc (NASDAQ: GANX) Trading Performance Indicators
Check out the current performance indicators for Gain Therapeutics Inc (GANX). In the past quarter, the stock posted a quick ratio of 1.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.75 in one year’s time.
Technical Analysis of Gain Therapeutics Inc (GANX)
Looking closely at Gain Therapeutics Inc (NASDAQ: GANX), its last 5-days average volume was 0.35 million, which is a jump from its year-to-date volume of 0.28 million. As of the previous 9 days, the stock’s Stochastic %D was 62.42%.
During the past 100 days, Gain Therapeutics Inc’s (GANX) raw stochastic average was set at 50.00%, which indicates a significant decrease from 58.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1634 in the past 14 days, which was higher than the 0.1495 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6773, while its 200-day Moving Average is $1.9106. However, in the short run, Gain Therapeutics Inc’s stock first resistance to watch stands at $1.9983. Second resistance stands at $2.1567. The third major resistance level sits at $2.2433. If the price goes on to break the first support level at $1.7533, it is likely to go to the next support level at $1.6667. Now, if the price goes above the second support level, the third support stands at $1.5083.
Gain Therapeutics Inc (NASDAQ: GANX) Key Stats
There are currently 35,949K shares outstanding in the company with a market cap of 66.15 million. Presently, the company’s annual sales total 0 K according to its annual income of -20,410 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -5,810 K.
